Phases, active trials: Phase 1: 16, Phase 2: 15, Phase 3: 20, Other: 7
Daiichi Sankyo has emerged as the global leader in antibody-drug conjugate (ADC) oncology through its proprietary DXd payload technology platform. Their collaboration with AstraZeneca on three blockbuster ADCs, Enhertu (trastuzumab deruxtecan, HER2), Dato-DXd (datopotamab deruxtecan, TROP2), and patritumab deruxtecan (HER3), has reshaped the competitive landscape in breast cancer, NSCLC, and gastric cancer. Enhertu's DESTINY-Breast and DESTINY-Gastric trials have set new benchmarks for HER2-low breast cancer and HER2-positive gastric cancer, expanding the HER2 targetable population. Daiichi Sankyo's wholly-owned pipeline includes ifinatamab deruxtecan (IFD, targeting B7-H3) for small cell lung cancer and other solid tumors, raludotatug deruxtecan (R-DXd, targeting CDH6) for ovarian and kidney cancers, and multiple DXd ADC combinations across indications.
- Breast cancer (HER2, HER2-low, TROP2, HER3)
- Non-small cell lung cancer (HER2, HER3, TROP2)
- Gastric / gastroesophageal cancer (HER2)
- Small cell lung cancer (B7-H3)
- Ovarian / renal cancer (CDH6)
- Enhertu (trastuzumab deruxtecan): HER2-targeting DXd ADC
- Dato-DXd (datopotamab deruxtecan): TROP2 DXd ADC
- Patritumab deruxtecan (HER3-DXd): HER3 DXd ADC
- Ifinatamab deruxtecan (I-DXd): B7-H3 DXd ADC, SCLC
- Raludotatug deruxtecan (R-DXd): CDH6 DXd ADC, ovarian/renal
- DS-6000: CDH6-targeting DXd ADC
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in… NCT06203210 | Primary completion moved at least 9 months later Primary endpoint removed | Recruiting |
8 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors NCT05875168 | Oct 20, 2026 · Estimated | Phase 1/2 |
This is the only one due in that window. See the calendar →
Monitor the Daiichi Sankyo pipeline daily
Get a daily digest when Daiichi Sankyo registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Advanced Solid Tumor | 8 |
| Breast Cancer | 4 |
| Non-small Cell Lung Cancer | 4 |
| Advanced Cancer | 3 |
| Metastatic Solid Tumor | 3 |
| Acute Myeloid Leukemia | 2 |
| Bladder Cancer | 2 |
| Endometrial Cancer | 2 |
Daiichi Sankyo registers ADC expansion trials across multiple tumor types continuously, every new Enhertu, Dato-DXd, or patritumab deruxtecan trial represents competitive intelligence for companies in breast cancer, NSCLC, and gastric cancer. Their pipeline of next-generation DXd ADCs (IFD for SCLC, R-DXd for ovarian) is closely watched for B7-H3 and CDH6 targeting precedent.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Daiichi Sankyo's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Daiichi Sankyo may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Daiichi Sankyo pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of DS-1103a Combination Therapy in Participants With Advanced Solid… NCT05765851 | Recruiting | Completion pushed from May 15, 2030 to Feb 28, 2031 | 2026-10-08 |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced… NCT04145622 | Active, Not Recruiting | Trial sites reduced: 28 → 23 locations | 2026-10-07 |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06172478 | Recruiting | Trial sites expanded: 91 → 94 locations | 2026-10-02 |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin… NCT06362252 | Recruiting | Completion pushed from Dec 30, 2026 to Feb 20, 2028 | 2026-10-02 |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab… NCT07701941 | Recruiting | Trial sites expanded: 0 → 72 locations | 2026-10-02 |
Each trial page shows every change DataLookout has recorded for that trial.